Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Novel Drug Therapies for the Treatment of Crohn's Disease
Pal Miheller1*, Agnes Anna Csontos1, Zsuzsanna Vegh1, András Gelley2 and Peter L. Lakatos1
12nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary
2Department of Internal Medicine and Gastroenterology, Polyclinic of the Hospitaller Brothers of St. John of God in Budapest, Hungary
- *Corresponding Author:
- Pal Miheller
2nd Department of Medicine
Semmelweis University, H-1088 Budapest
Szentkirályi u 46, Hungary
Tel: +36-63-4591500
Email: miheller.pal@med.semmelweis-univ.hu
Received date: May 07, 2015; Accepted date: June 05, 2015; Published date: June 12, 2015
Citation: Miheller P, Csontos AA, Vegh Z, Gelley A, Lakatos PL (2015) Novel Drug Therapies for the Treatment of Crohn's Disease. J Gastrointest Dig Syst 5:297. doi: 10.4172/2161-069X.1000297
Copyright: © 2015 Miheller, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.
Abstract
Introduction: There was a recent revolution in the medical therapy of inflammatory bowel disease with the advent of anti-TNF inhibitors. Treatment paradigms have evolved from a slow step-up approach to accelerated care with early introduction of immunosuppression and biologicals.
Areas covered: The authors review clinical efficacy and safety of new anti-TNFs and new action biologicals including anti-cytokine therapies and cell adhesion inhibitors in both Crohn’s disease. Some of the agents were already approved by both FDA and EMA.
Expert opinion: Anti-TNF agents will remain the mainstay of biological therapy in in Crohn’s disease in the near future. However; the proportion of anti-TNF refractory patient population is growing. In addition; there is a change in the cost structure of inflammatory dowel disease and anti-TNFs became responsible for a great proportion of the direct costs; therefore new biolologicals including biosimilar anti-TNFS are urgently awaited. The addition of these drugy into the armamentarium will provide additional treatment option for both bionaive and refractory patients and hopefully it will lead to improved outcomes and on the long run to a lesser economic burden of the disease.
